EAU 2021 | BMI and clinical outcomes in patients with metastatic castration-resistant prostate cancer
Matthew Galsky, MD, FASCO, Icahn School of Medicine at Mount Sinai, New York, NY, talks on the link between body mass index (BMI) and clinical outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel therapy, highlighting a survival benefit observed in patients with a higher BMI, and commenting on the potential implications of this finding. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.
Disclosures
Matthew Galsky, MD, FASCO, has a stock or other ownership interest in Rappta Therapeutics; has participated in a consulting or advisory role for BioMotiv, Janssen, Dendreon, Merck, GSK, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics, Basilea, Urogen, Infinity Pharmaceuticals and Gilead; and has received research funding from Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca and Genentech/Roche.
